Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer.
Zou LJ, Xiang QP, Xue XQ, Zhang C, Li CC, Wang C, Li Q, Wang R, Wu S, Zhou YL, Zhang Y, Xu Y.
Zou LJ, et al. Among authors: li cc, li q.
Acta Pharmacol Sin. 2019 Nov;40(11):1436-1447. doi: 10.1038/s41401-019-0237-5. Epub 2019 May 16.
Acta Pharmacol Sin. 2019.
PMID: 31097763
Free PMC article.